Research Article
Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results
Table 1
Patients’ characteristics at enrollment.
| | SLE () | HSs () | |
| Age (years) | 39 (35–46.25) | 40.5 (35–46.5) | ns | Sex (F/M) | 29/1 | 29/1 | ns | Disease duration (months) | 64 (31–99) | NA | | Antiphospholipid syndrome (N) | 9 | 0 | 0.0019 | Anti-dsDNA positivity (N) | 18 | 0 | <0.0001 | Hypcomplementemia C3 (N) | 19 | 0 | <0.0001 | C3 (g/l) | 0.69 (0.34–0.8) | 1.01 (0.96–1.2) | 0.0002 | Hypocomplementemia C4 (N) | 10 | 0 | 0.0008 | C4 (g/l) | 0.078 (0.03–0.115) | 0.15 (0.1–0.225) | 0.0039 | No prednisone (N) | 4 | 30 | <0.0001 | Prednisone ≤5 mg (N) | 13 | 0 | 0.0003 | Prednisone >5 mg | 13 | 0 | 0.0003 | Immunosuppressants (N) | 18 | NA | | Hydroxychloroquine (N) | 19 | NA | | Low dose aspirin (N) | 8 | 0 | 0.0046 | SELENA-SLEDAI | 4 (2–6.75) | NA | | BILAG A | 4 | NA | | BILAG B | 9 | NA | | SDI | 0.917 (0–1.04) | NA | |
|
|
NA: not applicable; ns: not significant.
|